Halozyme Proposes €2 Billion Takeover of Evotec at €11 Per Share, 27% Premium

Nov 14, 2024, 09:30 PM

Halozyme Therapeutics is reportedly exploring a takeover of the German drugmaker Evotec, with a proposed acquisition valued at approximately €2 billion ($2.1 billion). The offer includes a cash payment of €11 per share, representing a 27% premium over Evotec's last closing price. This potential acquisition aims to enhance Halozyme's drug discovery and development portfolio. The interest from Halozyme comes as Evotec has garnered attention in the biotechnology sector, with various reports confirming the ongoing discussions between the two companies.